As the inhibitors of PD-L1, which is encoded by the CD274 gene, are already in clinical use and the gene product of CD70 is another potentially interesting immunotherapy target, we focused on the CD274:CD70 interaction in the context of IFNγ expression in breast cancer. This evidence concerns the gene CD274 and breast carcinoma.